长非编码RNA在前列腺癌中的作用机制

doi:10.3760/cma.j.cn371439-20200610-00023

国际肿瘤学杂志 ›› 2021, Vol. 48 ›› Issue (2): 117-120.doi: 10.3760/cma.j.cn371439-20200610-00023

长非编码RNA在前列腺癌中的作用机制

张小飞, 胡建鹏, 崔飞伦()

江苏大学附属人民医院泌尿外科,镇江 212002

收稿日期:2020-06-10 修回日期:2020-06-23 出版日期:2021-02-08 发布日期:2021-03-11
通讯作者: 崔飞伦 E-mail:pdcuifeilun@163.com
基金资助:
江苏省自然科学基金(BK20191221);江苏省社会发展重点病种规范化诊疗项目(BE2016715);江苏省青年医学重点人才项目(QNRC2016457);江苏省卫生和计划生育委员会基金项目(H2017089)

Mechanism of long non-coding RNA in prostate cancer

Zhang Xiaofei, Hu Jianpeng, Cui Feilun()

Department of Urology Surgery, Affiliated People's Hospital of Jiangsu University, Zhenjiang 212002, China

Received:2020-06-10 Revised:2020-06-23 Online:2021-02-08 Published:2021-03-11
Contact: Cui Feilun E-mail:pdcuifeilun@163.com
Supported by:
Natural Science Fundation of Jiangsu Province of China(BK20191221);Social Development Plan of Jiangsu Provincial-Standardization of Key Disease Diagnosis and Treatment Project(BE2016715);Key Program for Young Medical Talent of Jiangsu Province of China(QNRC2016457);Commission of Health and Family Planning Foundation of Jiangsu Province of China(H2017089)

摘要/Abstract

摘要：

长非编码RNA(lncRNA)是一类转录本长度超过200个核苷酸、不能编码蛋白质的RNA分子。近年的研究表明,在机体的生理和病理过程中,lncRNA发挥重要作用,参与前列腺癌的发生、发展和转移。深入研究lncRNA在前列腺癌中的作用机制,有望为前列腺癌的诊断及治疗提供新的思路。

关键词: 前列腺肿瘤, RNA,长链非编码

Abstract:

Long non-coding RNA (lncRNA) is a type of RNA molecule whose transcript is longer than 200 nucleotides and cannot encode protein. Studies in recent years have shown that lncRNA plays an important role in the physiological and pathological processes of the body. It participates in the occurrence, development and metastasis of prostate cancer. Further study on the role and mechanism of lncRNA in prostate cancer is expected to provide new ideas for the diagnosis and treatment of prostate cancer.

Key words: Prostatic neoplasms, RNA, long noncoding

张小飞, 胡建鹏, 崔飞伦. 长非编码RNA在前列腺癌中的作用机制[J]. 国际肿瘤学杂志, 2021, 48(2): 117-120.

Zhang Xiaofei, Hu Jianpeng, Cui Feilun. Mechanism of long non-coding RNA in prostate cancer[J]. Journal of International Oncology, 2021, 48(2): 117-120.

参考文献 36

[1]	Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020[J]. CA Cancer J Clin, 2020,70(1):7-30. DOI: 10.3322/caac.21590. doi: 10.3322/caac.21590 pmid: 31912902
[2]	Chi Y, Wang D, Wang J, et al. Long non-coding RNA in the pathogenesis of cancers[J]. Cells, 2019,8(9):1015. DOI: 10.3390/cells8091015. doi: 10.3390/cells8091015
[3]	Cui Z, Ren S, Lu J, et al. The prostate cancer-up-regulated long noncoding RNA PlncRNA-1 modulates apoptosis and proliferation through reciprocal regulation of androgen receptor[J]. Urol Oncol, 2013,31(7):1117-1123. DOI: 10.1016/j.urolonc.2011.11.030. doi: 10.1016/j.urolonc.2011.11.030 pmid: 22264502
[4]	Yang Q, Cui ZL, Wang Q, et al. PlncRNA-1 induces apoptosis through the Her-2 pathway in prostate cancer cells[J]. Asian J Androl, 2017,19(4):453-457. DOI: 10.4103/1008-682X.178849. doi: 10.4103/1008-682X.178849 pmid: 27232851
[5]	Ghafouri-Fard S, Esmaeili M, Taheri M. H19 lncRNA: roles in tumorigenesis[J]. Biomed Pharmacother, 2020,123:109774. DOI: 10.1016/j.biopha.2019.109774. doi: 10.1016/j.biopha.2019.109774 pmid: 31855739
[6]	Zhu M, Chen Q, Liu X, et al. lncRNA H19/miR-675 axis represses prostate cancer metastasis by targeting TGFBI[J]. FEBS J, 2014,281(16):3766-3775. DOI: 10.1111/febs.12902. doi: 10.1111/febs.12902
[7]	Singh N, Padi SKR, Bearss JJ, et al. PIM protein kinases regulate the level of the long noncoding RNA H19 to control stem cell gene transcription and modulate tumor growth[J]. Mol Oncol, 2020,14(5):974-990. DOI: 10.1002/1878-0261.12662. doi: 10.1002/1878-0261.12662 pmid: 32146726
[8]	Ren S, Liu Y, Xu W, et al. Long noncoding RNA MALAT-1 is a new potential therapeutic target for castration resistant prostate cancer[J]. J Urol, 2013,190(6):2278-2287. DOI: 10.1016/j.juro.2013.07.001. doi: 10.1016/j.juro.2013.07.001 pmid: 23845456
[9]	Wang D, Ding L, Wang L, et al. LncRNA MALAT1 enhances oncogenic activities of EZH2 in castration-resistant prostate cancer[J]. Oncotarget, 2015,6(38):41045-41055. DOI: 10.18632/oncotarget.5728. doi: 10.18632/oncotarget.5728 pmid: 26516927
[10]	Wang F, Ren S, Chen R, et al. Development and prospective multicenter evaluation of the long noncoding RNA MALAT-1 as a diagnostic urinary biomarker for prostate cancer[J]. Oncotarget, 2014,5(22):11091-11102. DOI: 10.18632/oncotarget.2691.
[11]	Jin SJ, Jin MZ, Xia BR, et al. Long non-coding RNA DANCR as an emerging therapeutic target in human cancers[J]. Front Oncol, 2019,9:1225. DOI: 10.3389/fonc.2019.01225. doi: 10.3389/fonc.2019.01225 pmid: 31799189
[12]	Zhao HF, Zhang ZC, Shi BK, et al. DANCR sponges miR-135a to regulate paclitaxel sensitivity in prostate cancer[J]. Eur Rev Med Pharmacol Sci, 2019,23(16):6849-6857. DOI: 10.26355/eurrev_201908_18724. doi: 10.26355/eurrev_201908_18724 pmid: 31486484
[13]	Ma Y, Fan B, Ren Z, et al. Long noncoding RNA DANCR contri-butes to docetaxel resistance in prostate cancer through targeting the miR-34a-5p/JAG1 pathway[J]. Onco Targets Ther, 2019,12:5485-5497. DOI: 10.2147/OTT.S197009. doi: 10.2147/OTT.S197009 pmid: 31371987
[14]	Ji J, Dai X, Yeung SJ, et al. The role of long non-coding RNA GAS5 in cancers[J]. Cancer Manag Res, 2019,11:2729-2737. DOI: 10.2147/CMAR.S189052. doi: 10.2147/CMAR.S189052 pmid: 31114330
[15]	Xie X, Dai J, Huang X, et al. MicroRNA-145 inhibits proliferation and induces apoptosis in human prostate carcinoma by upregulating long non-coding RNA GAS5[J]. Oncol Lett, 2019,18(2):1043-1048. DOI: 10.3892/ol.2019.10419. doi: 10.3892/ol.2019.10419 pmid: 31423164
[16]	Yang J, Hao T, Sun J, et al. Long noncoding RNA GAS5 modulates α-Solanine-induced radiosensitivity by negatively regulating miR-18a in human prostate cancer cells[J]. Biomed Pharmacother, 2019,112:108656. DOI: 10.1016/j.biopha.2019.108656. doi: 10.1016/j.biopha.2019.108656 pmid: 30970507
[17]	Guo C, Qi Y, Qu J, et al. Pathophysiological functions of the lncRNA TUG1[J]. Curr Pharm Des, 2020,26(6):688-700. DOI: 10.2174/1381612826666191227154009. doi: 10.2174/1381612826666191227154009 pmid: 31880241
[18]	Xu T, Liu CL, Li T, et al. LncRNA TUG1 aggravates the progre-ssion of prostate cancer and predicts the poor prognosis[J]. Eur Rev Med Pharmacol Sci, 2019,23(11):4698-4705. DOI: 10.26355/eurrev_201906_18062. doi: 10.26355/eurrev_201906_18062 pmid: 31210308
[19]	Yang G, Yin H, Lin F, et al. Long noncoding RNA TUG1 regulates prostate cancer cell proliferation, invasion and migration via the Nrf2 signaling axis[J]. Pathol Res Pract, 2020,216(4):152851. DOI: 10.1016/j.prp.2020.152851. doi: 10.1016/j.prp.2020.152851 pmid: 32057513
[20]	Pu J, Wei H, Tan C, et al. Long noncoding RNA SNHG14 facilitates hepatocellular carcinoma progression through regulating miR-4673/SOCS1[J]. Am J Transl Res, 2019,11(9):5897-5904. pmid: 31632558
[21]	Li L, Zhang R, Li SJ. Long noncoding RNA SNHG14 promotes ovarian cancer cell proliferation and metastasis via sponging miR-219a-5p[J]. Eur Rev Med Pharmacol Sci, 2019,23(10):4136-4142. DOI: 10.26355/eurrev_201905_17915. doi: 10.26355/eurrev_201905_17915 pmid: 31173283
[22]	Ye T, Zhang N, Wu W, et al. SNHG14 promotes the tumorigenesis and metastasis of colorectal cancer through miR-32-5p/SKIL axis[J]. In Vitro Cell Dev Biol Anim, 2019,55(10):812-820. DOI: 10.1007/s11626-019-00398-5. doi: 10.1007/s11626-019-00398-5 pmid: 31471872
[23]	Xu ZN, Wang ZX, Xu L, et al. Long noncoding RNA SNHG14 exerts oncogenic functions in lung adenocarcinoma through acting as a sponge to miR-613[J]. Eur Rev Med Pharmacol Sci, 2019,23(24):10810-10817. DOI: 10.26355/eurrev_201912_19784. doi: 10.26355/eurrev_201912_19784 pmid: 31858549
[24]	Liu Z, Yan Y, Cao S, et al. Long non-coding RNA SNHG14 contributes to gastric cancer development through targeting miR-145/SOX9 axis[J]. J Cell Biochem, 2018,119(8):6905-6913. DOI: 10.1002/jcb.26889. doi: 10.1002/jcb.26889 pmid: 29667771
[25]	Ji N, Wang Y, Bao G, et al. LncRNA SNHG14 promotes the progression of cervical cancer by regulating miR-206/YWHAZ[J]. Pathol Res Pract, 2019,215(4):668-675. DOI: 10.1016/j.prp.2018.12.026. doi: 10.1016/j.prp.2018.12.026 pmid: 30611620
[26]	Sun B, Ke KB, Liu DF, et al. Long noncoding RNA SNHG14 acts as an oncogene in prostate cancer via targeting miR-613[J]. Eur Rev Med Pharmacol Sci, 2020,24(2):633-638. DOI: 10.26355/eurrev_202001_20039. doi: 10.26355/eurrev_202001_20039 pmid: 32016964
[27]	Ghafouri-Fard S, Taheri M. Maternally expressed gene 3 (MEG3): a tumor suppressor long noncoding RNA[J]. Biomed Pharmacother, 2019,118:109129. DOI: 10.1016/j.biopha.2019.109129. doi: 10.1016/j.biopha.2019.109129 pmid: 31326791
[28]	Li J, Zi Y, Wang W, et al. Long noncoding RNA MEG3 inhibits cell proliferation and metastasis in chronic myeloid leukemia via targeting miR-184[J]. Oncol Res, 2018,26(2):297-305. DOI: 10.3727/096504017X14980882803151. doi: 10.3727/096504017X14980882803151 pmid: 28653609
[29]	Wu M, Huang Y, Chen T, et al. LncRNA MEG3 inhibits the progression of prostate cancer by modulating miR-9-5p/QKI-5 axis[J]. J Cell Mol Med, 2019,23(1):29-38. DOI: 10.1111/jcmm.13658. doi: 10.1111/jcmm.13658 pmid: 30565858
[30]	Luo G, Wang M, Wu X, et al. Long non-coding RNA MEG3 inhi-bits cell proliferation and induces apoptosis in prostate cancer[J]. Cell Physiol Biochem, 2015,37(6):2209-2220. DOI: 10.1159/000438577. doi: 10.1159/000438577 pmid: 26610246
[31]	Zhang WY, Liu YJ, He Y, et al. Down-regulation of long non-coding RNA ANRIL inhibits the proliferation, migration and invasion of cervical cancer cells[J]. Cancer Biomark, 2018,23(2):243-253. DOI: 10.3233/CBM-181467. doi: 10.3233/CBM-181467 pmid: 30198868
[32]	Zhang JJ, Wang DD, Du CX, et al. Long noncoding RNA ANRIL promotes cervical cancer development by acting as a sponge of miR-186[J]. Oncol Res, 2018,26(3):345-352. DOI: 10.3727/096504017X14953948675449. doi: 10.3727/096504017X14953948675449 pmid: 28550682
[33]	Yu G, Liu G, Yuan D, et al. Long non-coding RNA ANRIL is associated with a poor prognosis of osteosarcoma and promotes tumorige-nesis via PI3K/Akt pathway[J]. J Bone Oncol, 2018,11:51-55. DOI: 10.1016/j.jbo.2018.02.002. doi: 10.1016/j.jbo.2018.02.002 pmid: 29520337
[34]	Deng W, Zhang Y, Cai J, et al. LncRNA-ANRIL promotes gastric cancer progression by enhancing NF-κB signaling[J]. Exp Biol Med (Maywood), 2019,244(12):953-959. DOI: 10.1177/1535370219860207. doi: 10.1177/1535370219860207
[35]	Ma J, Li T, Han X, et al. Knockdown of lncRNA ANRIL suppre-sses cell proliferation, metastasis, and invasion via regulating miR-122-5p expression in hepatocellular carcinoma[J]. J Cancer Res Clin Oncol, 2018,144(2):205-214. DOI: 10.1007/s00432-017-2543-y. doi: 10.1007/s00432-017-2543-y pmid: 29127494
[36]	Zhao B, Lu YL, Yang Y, et al. Overexpression of lncRNA ANRIL promoted the proliferation and migration of prostate cancer cells via regulating let-7a/TGF-β1/ Smad signaling pathway[J]. Cancer Biomark, 2018,21(3):613-620. DOI: 10.3233/CBM-170683. doi: 10.3233/CBM-170683 pmid: 29278879

长非编码RNA在前列腺癌中的作用机制

Mechanism of long non-coding RNA in prostate cancer

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 36

相关文章 15

编辑推荐

Metrics

本文评价

[1]	赵鑫, 范学武, 田龙, 胡逸民. 三维超声在前列腺癌图像引导放疗中的应用与评价研究[J]. 国际肿瘤学杂志, 2024, 51(1): 43-49.
[2]	金明, 甄书青, 王彦巧, 申红霞, 张爱民, 回丽妹. 丙泊酚对前列腺癌DU145细胞恶性生物学行为的影响及其机制[J]. 国际肿瘤学杂志, 2022, 49(8): 453-458.
[3]	张永丽, 张若佳, 范焕彩, 葛鲁娜, 王林. TXNDC5-Prx2途径对前列腺癌细胞耐药性的调控[J]. 国际肿瘤学杂志, 2021, 48(8): 473-478.
[4]	杜霄, 周菊英. 局限性前列腺癌的立体定向放疗[J]. 国际肿瘤学杂志, 2021, 48(5): 313-316.
[5]	刘振华. 前列腺癌治疗的最新进展:肿瘤精准治疗时代下转移性去势抵抗性前列腺癌患者的管理[J]. 国际肿瘤学杂志, 2021, 48(11): 702-704.
[6]	吉春冬, 刘凯, 冯越, 汪飞, 杨军, 薛荣波. PSAMR联合PI-RADS v2评分对高级别前列腺癌的预测价值[J]. 国际肿瘤学杂志, 2020, 47(12): 723-727.
[7]	张佳伟, 吴建臣. 外泌体在前列腺癌中的应用[J]. 国际肿瘤学杂志, 2020, 47(10): 634-636.
[8]	徐耀宗, 顾晓, 王飞, 丁雪飞. 雄激素剥脱治疗后前列腺癌发展为去势抵抗性前列腺癌的分子机制[J]. 国际肿瘤学杂志, 2018, 45(8): 506-509.
[9]	毕泗成，刘浩，张鹏，李喆，买铁军，祝志臻. 血清LCN2与PSA联合检测对前列腺癌的诊断价值[J]. 国际肿瘤学杂志, 2018, 45(1): 27-.
[10]	黄耿，姜卫东，毛青，桂定文. 微小RNA-206通过干扰CDK4和GAK的表达对前列腺癌细胞生长的影响[J]. 国际肿瘤学杂志, 2017, 44(7): 485-489.
[11]	周启东，蒋光亮，徐可. 糖皮质激素受体在泌尿系统恶性肿瘤中的研究进展[J]. 国际肿瘤学杂志, 2017, 44(6): 476-.
[12]	樊璐璐, 廖成功, 黄建国, 殷航, 钱门龙, 万闹, 卢宁. 化疗前血清胱抑素C对去势抵抗性前列腺癌预后的影响[J]. 国际肿瘤学杂志, 2017, 44(5): 356-360.
[13]	申骏龙,刘全海,刘莉,南淑良,程永毅,周建成. 改良13点前列腺穿刺活检在前列腺癌诊断中的应用 [J]. 国际肿瘤学杂志, 2017, 44(12): 907-910.
[14]	刘维帅,曾亚奇,邵月娟,王昆. 膳食纤维摄入与前列腺癌发生风险关系的Meta分析[J]. 国际肿瘤学杂志, 2016, 43(10): 758-764.
[15]	马强, 郑君芳, 焦延娜, 高红林, 李德冠, 刘鉴峰, 刘强, 宋娜玲. shRNA靶向干扰NHERF1对PC-3M前列腺癌细胞生物学行为的影响[J]. 国际肿瘤学杂志, 2015, 42(1): 14-17.